Prognostic Value of Handgrip Strength in Older Adults Undergoing Cardiac Surgery.


Journal

The Canadian journal of cardiology
ISSN: 1916-7075
Titre abrégé: Can J Cardiol
Pays: England
ID NLM: 8510280

Informations de publication

Date de publication:
11 2021
Historique:
received: 15 05 2021
revised: 13 07 2021
accepted: 09 08 2021
pubmed: 1 9 2021
medline: 5 1 2022
entrez: 31 8 2021
Statut: ppublish

Résumé

Although multidimensional frailty scales have been proven to predict mortality and morbidity in cardiac surgery, there is a need for rapid tools that could be easily administered at the point of care. Handgrip strength (HGS) is an attractive option that can be measured in acutely ill and bed-bound patients, although it has yet to be validated in a large cardiac surgery cohort. This is a post hoc analysis of a multicentre prospective study in older patients undergoing coronary artery bypass grafting and/or valve surgery from 2011 to 2019. HGS was measured before surgery and classified by sex-stratified cutoffs. The primary outcome was 1-year mortality and secondary outcomes were 30-day mortality, discharge disposition, and prolonged length of stay. There were 1245 patients included in the analysis (mean age 74.0 ± 6.6 years; 30% female). Weak HGS was associated with advanced age, heart failure, kidney disease, malnutrition, and various frailty scales. In those with weak vs normal HGS, respectively, 1-year mortality was 17% vs 6%, 30-day mortality was 10% vs 3%, prolonged length of stay was 34% vs 19%, and discharge to a health care facility was 45% vs 26% (all P < 0.001). After adjustment, HGS was predictive of 1-year and 30-day mortalities, with odds ratios of 2.44 (95% confidence interval [CI] 1.39-4.29) and 2.83 (1.38-5.81), respectively. HGS cutoffs of < 26 kg in men and < 16 kg in women had the highest predictive performance. HGS is a simple and effective tool to identify patients at higher risk of mortality and protracted recovery after cardiac surgery.

Sections du résumé

BACKGROUND
Although multidimensional frailty scales have been proven to predict mortality and morbidity in cardiac surgery, there is a need for rapid tools that could be easily administered at the point of care. Handgrip strength (HGS) is an attractive option that can be measured in acutely ill and bed-bound patients, although it has yet to be validated in a large cardiac surgery cohort.
METHODS
This is a post hoc analysis of a multicentre prospective study in older patients undergoing coronary artery bypass grafting and/or valve surgery from 2011 to 2019. HGS was measured before surgery and classified by sex-stratified cutoffs. The primary outcome was 1-year mortality and secondary outcomes were 30-day mortality, discharge disposition, and prolonged length of stay.
RESULTS
There were 1245 patients included in the analysis (mean age 74.0 ± 6.6 years; 30% female). Weak HGS was associated with advanced age, heart failure, kidney disease, malnutrition, and various frailty scales. In those with weak vs normal HGS, respectively, 1-year mortality was 17% vs 6%, 30-day mortality was 10% vs 3%, prolonged length of stay was 34% vs 19%, and discharge to a health care facility was 45% vs 26% (all P < 0.001). After adjustment, HGS was predictive of 1-year and 30-day mortalities, with odds ratios of 2.44 (95% confidence interval [CI] 1.39-4.29) and 2.83 (1.38-5.81), respectively. HGS cutoffs of < 26 kg in men and < 16 kg in women had the highest predictive performance.
CONCLUSIONS
HGS is a simple and effective tool to identify patients at higher risk of mortality and protracted recovery after cardiac surgery.

Identifiants

pubmed: 34464690
pii: S0828-282X(21)00661-9
doi: 10.1016/j.cjca.2021.08.016
pii:
doi:

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1760-1766

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2021 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.

Auteurs

Rosie Fountotos (R)

Division of Experimental Medicine, McGill University, Montréal, Québec, Canada; Centre for Clinical Epidemiology, Jewish General Hospital, Montréal, Québec, Canada.

Haroon Munir (H)

Division of Experimental Medicine, McGill University, Montréal, Québec, Canada; Centre for Clinical Epidemiology, Jewish General Hospital, Montréal, Québec, Canada.

Michael Goldfarb (M)

Division of Cardiology, Jewish General Hospital, McGill University, Montréal, Québec, Canada.

Sandra Lauck (S)

Division of Cardiology, St Paul's Hospital, University of British Columbia, Vancouver, British Columbia, Canada.

Dae Kim (D)

Division of Geriatric Medicine, Beth Israel Deaconess Medical Centre, Harvard University, Boston, Massachusetts, USA.

Louis Perrault (L)

Division of Cardiac Surgery, Montréal Heart Institute, University of Montréal, Montréal, Québec, Canada.

Rakesh Arora (R)

Division of Cardiac Surgery, St Boniface Hospital, University of Manitoba, Winnipeg, Manitoba, Canada.

Emmanuel Moss (E)

Division of Cardiac Surgery, Jewish General Hospital, McGill University, Montréal, Québec, Canada.

Lawrence G Rudski (LG)

Division of Cardiology, Jewish General Hospital, McGill University, Montréal, Québec, Canada.

Melissa Bendayan (M)

Division of Experimental Medicine, McGill University, Montréal, Québec, Canada; Centre for Clinical Epidemiology, Jewish General Hospital, Montréal, Québec, Canada.

Palina Piankova (P)

Division of Experimental Medicine, McGill University, Montréal, Québec, Canada; Centre for Clinical Epidemiology, Jewish General Hospital, Montréal, Québec, Canada.

Victoria Hayman (V)

Centre for Clinical Epidemiology, Jewish General Hospital, Montréal, Québec, Canada.

Julia Rodighiero (J)

Centre for Clinical Epidemiology, Jewish General Hospital, Montréal, Québec, Canada.

Marie-Claude Ouimet (MC)

Research Institute, McGill University Health Centre, Montréal, Québec, Canada.

Sarah Lantagne (S)

Centre for Clinical Epidemiology, Jewish General Hospital, Montréal, Québec, Canada.

Nicolo Piazza (N)

Division of Cardiology, McGill University Health Centre, Montréal, Québec, Canada.

Jonathan Afilalo (J)

Division of Experimental Medicine, McGill University, Montréal, Québec, Canada; Centre for Clinical Epidemiology, Jewish General Hospital, Montréal, Québec, Canada; Division of Cardiology, Jewish General Hospital, McGill University, Montréal, Québec, Canada; Research Institute, McGill University Health Centre, Montréal, Québec, Canada. Electronic address: jonathan.afilalo@mcgill.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH